Amgen Inc. buy melinda
Start price
24.03.18
/
50%
€155.86
Target price
04.06.18
€166.87
Performance (%)
8.04%
End price
04.06.18
€167.19
Summary
This prediction ended on 04.06.18 with a price of €167.19. The BUY prediction by melinda finished with a performance of 8.04%. melinda has a follow-up prediction for Amgen Inc. where he still thinks Amgen Inc. is a Buy. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Amgen Inc. | 0.441% | 0.441% | 8.898% | 13.389% |
| iShares Core DAX® | 0.336% | 4.366% | 21.868% | 63.911% |
| iShares Nasdaq 100 | 0.541% | 3.170% | 7.017% | 108.934% |
| iShares Nikkei 225® | 4.048% | 6.727% | 22.855% | 57.329% |
| iShares S&P 500 | 0.795% | 3.281% | 4.698% | 67.940% |
Comments by melinda for this prediction
In the thread Amgen Inc. diskutieren
SectorDrug Pharmaceuticals Agenda 24/04 Veröffentlichung der Ergebnisse
Amgen erhält positive CHMP-Stellungnahme Anerkennung von Repatha® (Evolocumab) verhindert Herzinfarkt und Schlaganfall Gepostet um 07:44 EST
Amgen (NASDAQ: AMGN) gab heute bekannt, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittel-Agentur (EMA) eine positive Stellungnahme angenommen hat, um eine neue Indikation in Repatha® aufzunehmen